^
Association details:
| Biomarker: | PTPN11 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Dasatinib response in acute myeloid leukemia is correlated with FLT3/ITD, PTPN11 mutations and a unique gene expression signature
Published date:
05/21/2020
Excerpt:
We performed ex vivo sensitivity screening to 46 drugs on 29 primary AML samples at diagnosis or relapse...mutations in FLT3/ITD and PTPN11 were enriched in the dasatinib sensitive samples as opposed to mutations in TP53 which were enriched in resistant samples.
DOI:
10.3324/haematol.2019.240705
Source:
Title:
DASATINIB RESPONSE IN AML IS CORRELATED WITH FLT3/ITD, PTPN11 MUTATIONS AND A UNIQUE GENE EXPRESSION SIGNATURE.
Published date:
05/14/2020
Excerpt:
Furthermore, mutations in FLT3/ITD and PTPN11were enriched in the dasatinib sensitive samples as opposed to mutations in TP53 which were enriched in resistant samples.
Source:
Title:
Dasatinib Inhibits FLT3/ITD and PTPN11mutated Acute Myeloid Leukemia Cells Overexpressing SRC Tyrosine Kinases
Published date:
11/06/2019
Excerpt:
...the IC50 for dasatinib in 23 carriers of the mutant PTPN11 was significantly lower compared to the IC50 of PTPN11 wild type samples (p=0.005).
DOI:
10.1182/blood-2019-128016
